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Abstract 
This paper examines the UK’s response to a recent European Clinical Trials 
Directive, namely the Department of Health, Central Office for Research Ethics 
Committee guidance, Governance Arrangements for NHS Research Ethics 
Committees. The revisions have been long awaited by researchers and research 
ethics committee members alike. They substantially reform the ethical review system 
in the UK. We examine the new arrangements and argue that though they go a long 
way toward addressing the uncertainty surrounding ethics committee function, the 
system favours the facilitation of research over the protection of the dignity and 
welfare of research participants. 
 
INTRODUCTION 
The recent clinical trials directive1 aims to standardise aspects of medical research 
across Europe. It endeavours to allow drugs that have been tested and licensed in 
one country to be adopted in another without further delay and research. It lays down 
requirements for research ethics committees, which will prompt revision of guidelines 
in a number of member states. Whilst the directive provides a framework, member 
states will have some latitude when revising their ethical review systems. In the UK, 
research ethics committees review not only clinical trials but also a wide range of 
other research protocols, ranging from epidemiological to qualitative research. The 
directive will necessitate legislation giving ethics committees statutory authority with 
regard to clinical trials and potentially the statute will be extended to cover their 
whole remit. Though reducing flexibility, this would ultimately give ethics committees 
the “teeth” they currently lack. The response to date, however, has not been 
encapsulated in statute but in guidance from the Department of Health, Central 
Office for Research Ethics Committees, namely the Governance Arrangements for 
NHS Research Ethics Committees.2 
 
The guidance seeks to interpret elements of good clinical practice ensconced in the 
directive, but applies not only to clinical trials, but to all areas of National Health 
Service (NHS) research. The governance arrangements are to be read in 
conjunction with the Department of Health Research Governance Framework for 
Health and Social Care.3 
 
We argue that the new arrangements go a long way toward addressing the 
uncertainty surrounding ethics committee function. The clinical trials directive was, 
however, industry-led and its interpolation into UK guidance has led to a subtle 
change of emphasis from the protection of research participants to the facilitation of 
research. 
 
BRIEF HISTORY OF UK RESEARCH ETHICS COMMITTEES 
In the UK a centralised system of research ethics committees was introduced as late 
as 1991.4 At least one independent “local research ethics committee” was set up in 
each district in order to advise NHS bodies which research should go ahead.  
 
Local research ethics committees are funded by local health authorities, but remain 
independent. Until recently, each committee had up to 12 members, and included 
individuals from a range of medical and lay positions. Working procedures were 
largely left to each committee and funding was sporadic. In 1991 there was little to 
impel consistency between committees, though they were asked to “cooperate” in 
multicentre research applications. It soon emerged that the system was at best 
inconsistent and at worst prohibitive of research, particularly in the case of 
multicentre trials. 
 
The result was a spate of empirical research outlining disgruntled researchers’ 
complaints about the system.5 They detailed the different procedures demanded by 
each committee, the time delays and the inconsistencies. This weight of opinion 
coincided with a desire to put in place a system whereby the UK could give one 
definitive ethical review of a protocol that would take place across a number of 
European countries, prompted by the pending introduction of the clinical trials 
directive. The result was that in 1997 the introduction of “multicentre research ethics 
committees”6 temporarily reduced the onslaught of complaints by multicentre 
researchers. 
 
Where health care research involved five or more local research ethics committee 
geographical sites, the application would instead be put to one multicentre research 
ethics committee. Unfortunately this method failed to address the inadequate 
financing, training, and guidance available to local research ethics committees. Part 
of the remit of the local research ethics committee is, as their name suggests, to 
consider local issues. They may, for example, feel that a research population has 
been involved in research excessively and refuse to approve the protocol. Therefore 
a multicentre protocol would go to the multicentre research ethics committee which 
would rule on whether it was ethical. It would then go on to each local research 
ethics committee for consideration of local issues. “Pertinent local issues” were, 
however, poorly defined. In some instances the local research ethics committee did 
not even pretend that their concern was with local issues. When they recognised a 
matter of ethical concern they wrote to the multicentre research ethics committee, 
which was often too busy to respond. As a result some local research ethics 
committees withheld approval.7 A renewed spate of empirical research emphasised 
researchers’ continuing complaints about the research ethics committee system.  
 
Consequently the chief medical officer  issued interim guidance better defining the 
contentious term “pertinent local issues” and attempting to reduce time delays by 
allowing expedited review outside the normal committee cycle.8 Though the 
guidance clarified the situation it did notend the problems associated with multicentre 
review.9 Further, little had been done to aid consistency in local research ethics 
committee review. When applying to four different local research ethics committees it 
was quite possible to have to fill in four different forms, present a verbal explanation 
to some committees, and receive a mixture of favourable and unfavourable 
responses over a long period of time.10 Researchers viewed the research ethics 
committee system as an unduly overbearing one. They felt that ethical review often 
delayed or even prevented research that could benefit the population.11 In the light 
of this, the European clinical trials directive, and a number of research scandals, it 
became clear that a comprehensive review of the system was necessary. 
Consequently in 2001 the governance arrangements replaced the health service 
guidelines of 1991 and 1997. 
 
WHAT NEEDED TO BE DONE? 
The Declaration of Helsinki states at article 5: “In medical research on human 
subjects, considerations related to the wellbeing of the human subject should take 
precedence over the interests of science and society”.12 It is perhaps this that the 
ethics committee reveres above all other principles. Delays, bureaucracy, and 
expense are undesirable but acceptable if they are necessary to achieve this goal. 
Prior to the new governance arrangements ethics committee members suffered 
inadequate guidance, poor funding, lack of facilitated communication between 
committees, and poor access to training. Members come largely from busy 
professions where time is at a premium. Yet neither they, nor their employer were 
paid for the time they spent preparing for and attending meetings. It seems that to 
fulfil article 5 of the Declaration of Helsinki, the independent ethics committee must 
continue to place the wellbeing of the participant above the interests of science and 
society. Yet the system must be better resourced and guided so as to reduce 
bureaucracy and thereby facilitate ethical research. 
 
The new arrangements undoubtedly address the vital issues of resourcing ethics 
committees and reducing bureaucracy. They go beyond this, however, and it is 
questionable whether this is in the interests of the furtherance of article 5 of the 
Declaration of Helsinki. On a close examination of the literature detailing complaints 
from the research community, issues of delay and bureaucracy feature strongly. 
There is also an underlying notion, however, that the ethics committees’ insistence 
on participant wellbeing is disproportionately balanced with the value of medical 
science. Some commentators argue that the ethics committees’ remit should be 
reduced—for example, to prevent them reviewing legal or scientific aspects of the 
protocol,13 or to keep local research ethics committees out of multicentre research 
review.14 The confidence of researchers in the ethical review system has diminished 
amid complaints that local research ethics committees frequently ignore the 
guidance relating to operational procedures,15 lack accountability, and do not 
adequately justify their decisions.16 Ethics committees were perceived as getting in 
the way of valuable research. It created a danger that the UK would not be seen as a 
viable site for lucrative international research. What resulted was pressure, 
particularly from industry, to refine the remit and freedom of research ethics 
committees in the interests of facilitating research. 
 
In May 2001 a European directive was enacted which, in part, sought to standardise 
the function of ethics committees. Coming into force in 2004, the directive seeks to 
make binding elements of the good clinical practice guidelines produced by the 
International Conference on Harmonisation.17 The aim of “good clinical practice” 
undoubtedly constitutes an element of good ethical clinical practice, and the directive 
is based in part on the Declaration of Helsinki. Article 9 of the directive provides that: 
“No clinical trial can commence until an appropriate ethics committee approves the 
protocol”. The directive is, however, equally concerned with procedural conformity. 
Thus, “good clinical practice” is as much a question of facilitating research as it is of 
ensuring that research is ethical. The aim is to ensure that Europe is an attractive 
location for lucrative research. It applies to clinical trials, many of which will be 
multicentred and commercially sponsored. It requires each member state to make 
one single opinion with regard to multicentre research, even if that research is limited 
to one member state.18 
 
The research ethics committee governance arrangements build upon these 
foundations. Taken together, the new guidance will produce a number of favourable 
outcomes with regard to ethics committee procedure and consistency. The clinical 
trials directive was, however, industry-led and this is reflected in the governance 
arrangements. In terms of clinical research, the interests of industry will come to the 
fore. In terms of other types of research, the facilitation of research is given  
increasing significance over the protection of research participants. Paragraph 1.1 
outlines the essential nature of research and the research ethics committee’s duty to 
enable relevant research of good quality. The fact that this principle is stated first and 
foremost surely stands testament to its prominence. This principle potentially stands 
in opposition to article 5 of the Declaration of Helsinki which demands that “the 
well-being of the human subject should take precedence over the interests of 
science and society”. Paragraph 1.3 of the governance arrangements states that the 
dignity, rights, safety, and wellbeing of participants must be the primary 
consideration in a research study. Later, in paragraph 2.3, more concession is made 
to article 5 of the Helsinki Declaration. It states that the goals of research are 
secondary to the interests of participants. However, the fact that paragraph 1.3 does 
not state that participants’ interests are the primary consideration of the ethics 
committee and that the arrangements do not put primary consideration on the 
principle by placing it numerically before and expressly above paragraph 1.1, is 
worrying. Though subtle, the wording marks a step away from protection of the 
research participant as the factor of paramount importance and instead asks the 
ethics committee to balance this with the furtherance of medical science. A number 
of provisions in the governance arrangements limit the remit of ethics committees 
and make it potentially more difficult for research participants to be given paramount 
protection. 
 
APPLICATION OF ‘RECOGNISED ETHICAL STANDARDS’ 
In paragraph 2.1—for example, it is stated that research ethics committees should 
provide independent advice to relevant parties as to the extent to which proposals 
comply with recognised ethical standards. Taken literally, researchers might have a 
legitimate complaint if ethics committees rule that a protocol is unethical and the 
committees have not applied recognised ethical standards to back up their advice.  
 
Perhaps ethics committees should have trained ethicists as members so that in any 
novel situation (where there are no recognised standards to apply) they can 
nevertheless apply philosophically relevant standards. This is unlikely to be the 
required outcome of the arrangements as there is no mention that ethicists should be 
included on the committee or that training should radically improve members’ 
understanding of moral philosophy. Otherwise, paragraph 2.2 might imply that 
Department of Health ethical guidelines should always be considered and applied. 
Ethics committees would welcome comprehensive guidance on every aspect of 
health care research. There would, however, be little need for the humble ethics 
committee if that ever became the reality. Research is constantly evolving and 
changing and ethics committees must be prepared to deal with novel situations for 
which there is limited ethical guidance. Rarely are ethical standards absolute. Ethics 
committees will have to give advice where ethical standards are in the process of 
being developed and debated. Consequently a researcher could argue that a 
standard promotes his research and the ethics committee could quote standards that 
render it unacceptable. 
 
PROHIBITION ON LEGAL INTERPRETATION 
The arrangements create some confusion in relation to the ethics committees’ 
required knowledge and application of law. Paragraph 2.6 states that: “Research  
ethics committees should have due regard for the requirements of relevant 
regulatory agencies and of applicable laws”, but that “it is not for the [research ethics 
committee] to provide specific interpretation of regulations or laws, but it may 
indicate in its advice to the researcher and host institution where it believes further 
consideration needs to be given to such matters”. This is likely to cause confusion, 
as having due regard to regulations and laws necessarily involves an element of 
interpretation. As HLA Hart’s famous example shows, even an apparently simple 
legal statement like “No vehicles are allowed in the park” require interpretation to be 
applied.19 A car is clearly a vehicle, but what about motorcycles, bicycles or 
skateboards? Further, it might be argued by researchers that ethics committees 
have no power to withhold approval on the basis that the trial is in some way illegal, 
as the arrangements only allow them to indicate a need for further consideration. 
The law represents a minimum standard of conduct which ethics complements and 
builds upon. The essence of the arrangements is to ensure that ethics committees 
are mindful of legal principles but are not hindered by the necessity to get involved in 
minute interpretation. Yet, this provision has the potential to be abused by limiting 
the remit of the ethics committee to matters free of any legal interpretation. 
 
PROHIBITION ON SCIENTIFIC REVIEW 
A similar situation has developed in relation to ethics committees’ consideration of 
scientific aspects of research. The original guidance to local research ethics 
committees, (HSG(91)5),4 required committees to look at protocols on the basis of 
three different approaches. Patient welfare involved a duty-based approach, patient 
dignity a rights-based approach, and scientific validity a goal-based approach. It 
seems that much of the latter element is to be lost. 
 
Article 6 of the clinical trials directive provides that the research ethics committee is 
responsible for determining the relevance of the clinical trial and the trial design. This 
has been interpreted for the purposes of paragraph 9.13 of the governance 
arrangements so as to demand that research ethics committees are “adequately 
reassured” about the appropriateness of study design, risks and benefits, use of 
controls, criteria for withdrawing participants, adequacy of the monitoring 
arrangements, research site, and manner in which the research will be reported. By 
virtue of paragraph 9.9, however, it seems that the means of reassurance is not 
through review of the protocol, but through assessment of prior review by experts in 
the relevant research methodology. If the ethics committee is not satisfied that the 
prior review is adequate, paragraph 9.10 allows them to require resubmission. The 
requirement that ethics committees do not review scientific aspects of the protocol 
does not come from the European directive. Neither does it come from the research  
governance framework which states that: “All proposals for health and social care 
research must be subjected to review by experts in the relevant fields able to offer 
independent advice on its quality”. This does not preclude scientific review by the 
research ethics committee. So it is a novel means of dealing with the scientific 
aspects of the protocol and it is likely to be problematic. Not only might it be difficult 
for the committee to separate the scientific review and the process of review, but 
there are different schools of thought within the field of research methodology which 
may make the review of process more difficult and controversial than it first appears. 
 
LOCALITY REVIEW 
In relation to multicentre research (involving five or more sites), the multicentre 
research ethics committee will review the ethics of the protocol. In parallel, each 
local research ethics committee will look at carefully defined locality issues. This 
presents potential difficulties in that the committee may require access to the 
reviewed protocol. The local research ethics committee might need to know what 
changes the multicentre research ethics committee has demanded in order to 
properly assess locality issues. 
 
Time limits have recently been placed on the review process in the UK with the result 
that expedited review of local issues in multicentre trials takes place occasionally 
with as few as two local research ethics committee members. Some commentators 
believe this to be unethical.20 It potentially reduces the protection afforded to 
research participants. Nevertheless, the governance document leaves each 
committee to make its own arrangements for expedited review and does not 
expressly limit its use to cases of “locality issue” review. 
 
The revision of guidance to ethics committees has been long awaited. The result is 
comprehensive and will benefit researchers and ethics committees in a number of 
ways. The function of ethics committees is better defined. Their funding and training 
requirements are secured. The benefits are marred, however, by an underlying 
emphasis on facilitating research to the extent that there is potential for it to 
adversely affect the interests of individual research participants. Though in total 
accordance with the clinical trials directive, this marks a small but significant step 
away from the principles ensconced in the Declaration of Helsinki. 
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